| NASDAQ (usa) |   | 6715.56 | -12.11 | -0.18% | 
| FTSE 100 (london) |  | 7487.96 | -5.12 | -0.07% | 
| DAX (german) |   | 13465.51 | 235.94 | 1.78% | 
| NIKKEI 225 (japan) |   | 22420.08 | 408.47 | 1.86% | 
| Hang - Seng (hong kong) |   | 28594.06 | 348.52 | 1.23% | 
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |   | 3391.61 | 17.53 | 0.52% | 
| KOSPI (korea) |   | 2556.47 | 33.04 | 1.31% | 
| All Ordinaries (australia) |   | 6005.30 | 28.90 | 0.48% | 
| BOVESPA (brazil) |   | 74092.76 | -215.73 | -0.29% | 
Idorsia Ltd (SW: IDIA)
                                    	IDIA Technical Analysis
                                    
                                    
    5
    
    
    
    
									| As on 30th Oct 2025 IDIA STOCK Price closed @ 3.32 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.46 & Strong Buy for SHORT-TERM with Stoploss of 2.25 we also expect STOCK to react on Following IMPORTANT LEVELS. | 
IDIASTOCK Price
| Open | 3.40 | Change | Price | % | 
| High | 3.49 | 1 Day | -0.06 | -1.78 | 
| Low | 3.05 | 1 Week | -0.39 | -10.51 | 
| Close | 3.32 | 1 Month | -0.55 | -14.21 | 
| Volume | 3296373 | 1 Year | 0.97 | 41.28 | 
| 52 Week High 4.70 | 52 Week Low 0.63 | ||||
    SW Switzerland Most Active Stocks
                    | CSGN | 0.82 | 0.00% | 
| CSGN | 0.82 | 0.00% | 
| UBSG | 30.68 | 0.26% | 
| UBSG | 30.68 | 0.26% | 
| SIGN | 8.62 | -2.16% | 
| NESN | 77.45 | -1.30% | 
| NESN | 77.45 | -1.30% | 
| IDIA | 3.32 | -1.78% | 
| ABBN | 59.96 | 0.60% | 
| ABBN | 59.96 | 0.60% | 
SW Switzerland Top Gainers Stocks
                    
                SW Switzerland Top Losers Stocks
                    
                | IDIA Daily Charts | IDIA Intraday Charts | Whats New @ Bazaartrend | IDIA Free Analysis | 
|  | 
IDIA Important Levels Intraday
                                    | RESISTANCE | 4.17 | 
| RESISTANCE | 3.90 | 
| RESISTANCE | 3.73 | 
| RESISTANCE | 3.56 | 
| SUPPORT | 3.08 | 
| SUPPORT | 2.91 | 
| SUPPORT | 2.74 | 
| SUPPORT | 2.47 | 
IDIA Forecast  October 2025
                                    | 4th UP Forecast | 5.19 | 
| 3rd UP Forecast | 4.59 | 
| 2nd UP Forecast | 4.22 | 
| 1st UP Forecast | 3.85 | 
| 1st DOWN Forecast | 2.79 | 
| 2nd DOWN Forecast | 2.42 | 
| 3rd DOWN Forecast | 2.05 | 
| 4th DOWN Forecast | 1.45 | 
     IDIA Weekly Forecast
                                    
                                    
                                | 4th UP Forecast | 4.28 | 
| 3rd UP Forecast | 3.97 | 
| 2nd UP Forecast | 3.78 | 
| 1st UP Forecast | 3.59 | 
| 1st DOWN Forecast | 3.05 | 
| 2nd DOWN Forecast | 2.86 | 
| 3rd DOWN Forecast | 2.67 | 
| 4th DOWN Forecast | 2.36 | 
IDIA Forecast2025
                                    | 4th UP Forecast | 11.49 | 
| 3rd UP Forecast | 8.87 | 
| 2nd UP Forecast | 7.25 | 
| 1st UP Forecast | 5.63 | 
| 1st DOWN Forecast | 1.01 | 
| 2nd DOWN Forecast | -0.61 | 
| 3rd DOWN Forecast | -2.23 | 
| 4th DOWN Forecast | -4.85 | 
                                        Idorsia Ltd ( SW Switzerland Symbol : IDIA ) 
Sector : Healthcare And Other Stocks in Same Sector
                                    
                                    
                                Sector : Healthcare And Other Stocks in Same Sector
IDIA Other Details
                    | Segment | EQ | |
| Market Capital | 3191988736.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > echo $website ; ?> | |
IDIA Address
                                 |  | ||
                                        IDIA Latest News
                                    
                                    
                                    IDIA Business Profile
   
	 Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland. Address: Hegenheimermattweg 91, Allschwil, Switzerland, 4123 
	
            
            © 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
 
	   Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

